Innovation in biomaterials: how they are validated prior to implantation

Innovation in biomaterials has transformed the design and performance of implantable medical devices. New metal alloys, advanced polymers, technical ceramics and bioactive coatings are enabling the development of implants that are more durable, biocompatible and adapted to today’s clinical requirements.

However, before a biomaterial can be used in a surgical implant, it must pass a rigorous technical, biomechanical and biological validation process, aligned with Regulation (EU) 2017/745 (MDR). In this article, we explain how biomaterials are evaluated prior to implantation and which tests are essential to ensure their safety and performance.

What is considered a biomaterial in medical devices?

A biomaterial is any material designed to interact with biological systems for therapeutic or diagnostic purposes. In implantable medical devices, biomaterials must simultaneously meet the requirements of:

  • biocompatibility,
  • mechanical resistance,
  • chemical stability,
  • long-term durability,
  • compatibility with manufacturing and sterilization processes.

These materials must not only be safe in isolation, but also maintain their performance when part of a complete device.

Types of biomaterials used in implants

Biomaterials innovation encompasses different families, each with specific validation challenges.

Type of biomaterialCommon examplesCommon applications
MetallicsTi6Al4V, CoCr, stainless steelJoint prostheses, bone plates
CeramicsAlumina, zirconiaJoint components, femoral heads
PolymericsPEEK, UHMWPEAcetabular components, fixations
BioactivesHydroxyapatite, calcium phosphatesOsseointegrative coatings
CompoundsMultilayer, hybridsNew generation implants

Each category requires specific tests, as their behavior under load, wear or biological environment is different.

Why pre-implementation validation is critical

An innovative biomaterial may offer theoretical advantages, but without proper validation it may generate serious risks, such as:

  • implant fracture,
  • accelerated wear,
  • particle release,
  • adverse tissue reactions,
  • premature failure in clinical use.

Therefore, the MDR requires demonstrating that the selected materials are safe and suitable for the intended use, supported by objective data obtained through standardized testing and scientific evaluation.

innovation-in-biomaterials

Key mechanical testing in the validation of biomaterials

Mechanical testing verifies that the biomaterial can withstand the actual loads to which the implant will be subjected.

Type of testTargetStandard rules
Tensile and compression testsDetermine strength and yield strengthISO 6892, ASTM E8
Fatigue testsEvaluate behavior under cyclic loadingISO 7206-4, ASTM F384
Bending testsAnalyze structural stiffnessISO 9585, ASTM F382
Wear testsMeasuring material lossISO 14242, ASTM F732
Adhesion testsValidate coatingsASTM F1147, ASTM F1044

These tests are particularly relevant for implants subjected to millions of load cycles, such as joint prostheses or osteosynthesis systems.

Biological and chemical evaluation of the biomaterial

In addition to mechanical behavior, the biomaterial must demonstrate that it is biologically safe. The ISO 10993 series establishes the reference framework for this evaluation.

Type of evaluationWhat it analyzes
CytotoxicityDirect cell damage
AwarenessAllergic reactions
IrritationLocal tissue response
Systemic toxicityEffects on the organism
Chemical degradationLong-term stability

In degradable or bioactive materials, degradation kinetics and controlled release of products are also studied.

Relationship between biomaterials, assays and MDR 2017/745.

The MDR requires manufacturers to justify the selection of materials within the technical file by demonstrating that:

  • the biomaterial is suitable for the intended use,
  • associated risks are identified and mitigated,
  • the tests performed are representative,
  • the results are traceable and reproducible.

For this reason, the tests used as regulatory evidence are usually performed in ISO/IEC 17025 accredited laboratories, which reinforces the acceptance of the data by the notified bodies.

IBV’s role in the validation of biomaterials

The Biomechanics Institute of Valencia combines the capabilities of:

  • advanced mechanical testing,
  • analysis of fatigue and wear behavior,
  • applied biomechanical evaluation,
  • technical support in MDR validation strategies.

This allows manufacturers to validate innovative biomaterials prior to clinical implantation, reducing technical and regulatory risks and accelerating market access.

Frequently asked questions about validating implantable biomaterials

Why must a biomaterial be validated before implantation? Because it must be shown to be safe, strong and biocompatible under real conditions of use, avoiding risks to the patient and device failures.
Which mechanical tests are most common for implantable biomaterials? Tensile, fatigue, bending, wear and adhesion tests, adapted to the type of material and the intended use of the implant.
Which standards govern the biological evaluation of biomaterials? Mainly the ISO 10993 series, which sets out methods to evaluate cytotoxicity, sensitisation, toxicity and degradation.
Does the MDR specifically require biomaterials to be validated? Yes. The MDR requires the choice of materials to be justified and technical and biological evidence to be provided that supports their safety and performance.
How does IBV support the validation of innovative biomaterials? IBV performs mechanical and biomechanical tests, interprets the results and advises manufacturers on generating valid evidence for MDR compliance.
Medical Device Testing in Europe: A Guide for International Manufacturers

Medical Device Testing in Europe: A Guide for International Manufacturers

For a medical device manufacturer based outside the European Union, selecting a testing laboratory in Europe can be a strategic decision. It is not merely a matter of completing a…

How to Measure the Outcomes of Robotic Rehabilitation Through Gait Analysis: The Lokomat Case Study

How to Measure the Outcomes of Robotic Rehabilitation Through Gait Analysis: The Lokomat Case Study

The incorporation of robots and exoskeletons into neurorehabilitation programs opens up new possibilities for intensifying gait training. However, for hospitals, developers, and manufacturers of healthcare technology, it is not enough…

QMSR, Quality Management System Regulation. What changes for a manufacturer that exports to multiple markets

QMSR, Quality Management System Regulation. What changes for a manufacturer that exports to multiple markets

For years, comparing ISO 13485 with the U.S. Quality System Regulation meant maintaining two parallel frameworks: the international standard and the detailed requirements of 21 CFR Part 820. As of…